甲基莲心碱联合伊马替尼对慢性粒细胞白血病原代细胞Akt/p-Akt蛋白表达的影响  

Effect of Neferine combined with Imatinib on Akt/p-Akt protein expression in primary cells of chronic myelogenous leukemia

作　　者：何思润[1] 胡敏[1] 秦群[1] 杨瑞[1] 

机构地区：[1]中南大学湘雅医院,湖南长沙410008

出　　处：《中国现代医学杂志》2015年第30期37-39,共3页China Journal of Modern Medicine

摘　　要：目的探讨甲基莲心碱(Nef)联合伊马替尼(IM)对慢性粒细胞白血病(CML)原代细胞Akt/p-Akt表达的影响。方法采用Western blot法分别检测Akt/p-Akt蛋白的表达水平。结果 Nef(4μmol)、IM(1μmol)单药组与Nef(4μmol)+IM(1μmol)联合用药组,对CML原代细胞Akt蛋白的表达均无影响(P>0.05),而p-Akt蛋白表达均降低,且联合用药组较单药组蛋白表达更低(P<0.05)。结论 Nef联合伊马替尼能够降低CML原代细胞p-Akt蛋白表达,可能是甲基莲心碱增强伊马替尼对CML原代细胞敏感性的机制之一。【Objective】 To investigate the effect of a combination of Neferine and Imatinib on Akt/p-Akt protein expression in chronic myelogenous leukemia（CML） primary cells.【Methods】 Akt/p-Akt protein expression was detected by Western blot.【Results】 Neither Neferine（4 μmol）,Imatinib（1 μmol） alone nor their combination had influence on the Akt protein expression in CML primary cells（P〉0.05）.On the contrary,pAkt expression was reduced in the three groups,and even lower in the combination group（P〈0.05）.【Conclusions】 p-Akt protein expression is reduced by the combination of Neferine and Imatinib,which may be one of the mechanisms of Neferine sensitizing CML primary cells to Imatinib.

关 键 词：甲基莲心碱 慢性粒细胞白血病原代细胞 P-AKT AKT 

分 类 号：R557.3[医药卫生—血液循环系统疾病]